11 Most Expensive Stocks Insiders Are Buying Recently

3. Merck & Co., Inc. (NYSE:MRK)

Average price per share: $88.38

Market capitalization: $222.71 billion

The third among the 11 most expensive stocks insiders are buying recently is a New Jersey-based global healthcare company that develops treatments for oncology, immunology, neuroscience, virology, cardiovascular diseases, and diabetes. Merck & Co. also runs an animal health division concentrated on veterinary pharmaceuticals, vaccines, and health management solutions. It is a dividend-paying stock and one of 13 cheap high dividend stocks to invest in now.

The company recently announced it has received European Commission conditional approval for WELIREG (belzutifan), the first oral HIF-2α inhibitor in the EU, for two indications: treatment of adult patients with von Hippel-Lindau (VHL) disease and advanced clear cell renal cell carcinoma.

In February, two insiders bought a total of around $1.58 million worth of Merck & Co. shares at an average price of $88.38 per share. Currently, the stock is trading at $88.00 per share, having lost 11.55% since the beginning of the year. Over the past 12 months, the stock declined 31.31%, and it is possible that insiders wanted to use the current drop to acquire shares at a more affordable price.

In 2024, the company had sales of $64.16 billion, compared to $60.12 billion in 2023.

As per the opinion of 17 analysts, Merck & Co. is a “Buy.” A 12-month price target is projected at $120.31, data from StockAnalysis reveals.